Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-1755PMID 17145896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Requirement for CDK4 kinase function in breast cancer.

  2006cited by this paper
• Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

  2006cited by this paper
• Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

  2005cited by this paper
• Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression

  2005cited by this paper
• Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.

  2005cited by this paper
• Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [99mTc]peptide-peptide nucleic acid-peptide chimera.

  2005cited by this paper
• Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1.

  2005cited by this paper
• Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• FDG-PET in monitoring therapy of breast cancer

  2004cited by this paper
• Selective estrogen receptor modulation: concept and consequences in cancer.

  2004cited by this paper
• Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.

  2004cited by this paper
• Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• A prognostic index for operable, node-negative breast cancer

  2004cited by this paper
• External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras.

  2004cited by this paper
• Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

  2004cited by this paper
• Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

  2003cited by this paper
• Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.

  2003cited by this paper
• Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays

  2002cited by this paper
• Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.

  2002cited by this paper
• Endocrine-responsive breast cancer and strategies for combating resistance

  2002cited by this paper
• Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells

  2002cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001cited by this paper
• Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor).

  2001cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• Reduction in cyclin D1/Cdk4/retinoblastoma protein signaling by CRE-decoy oligonucleotide.

  2001cited by this paper
• PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells

  2001cited by this paper
• Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells.

  2001cited by this paper
• Molecular and pharmacological aspects of antiestrogen resistance.

  2001cited by this paper
• Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

  2001cited by this paper
• A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence*

  2000cited by this paper
• Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.

  2000cited by this paper
• Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity.

  2000cited by this paper
• The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation.

  1999cited by this paper
• Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.

  1999cited by this paper
• c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry

  1998cited by this paper
• A Specific Role for Cyclin D1 in Mammary Gland Development

  1997cited by this paper
• Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution

  1997cited by this paper
• Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.

  1997cited by this paper
• Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint

  1996influential reference
• Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.

  1996cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines.

  1994cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar.

  1990cited by this paper
• Tamoxifen flare in advanced breast cancer.

  1978cited by this paper

• Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

  2025cites this paper
• Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation

  2025cites this paper
• Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets

  2025cites this paper
• Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer

  2025cites this paper
• Naringenin impairs mitochondrial function via ROS to induce apoptosis in tamoxifen resistant MCF-7 breast cancer cells

  2025cites this paper
• A circRNA–mRNA pairing mechanism regulates tumor growth and endocrine therapy resistance in ER-positive breast cancer

  2025cites this paper
• OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer.

  2024cites this paper
• Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition

  2024cites this paper
• Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations

  2024cites this paper
• Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells

  2024cites this paper
• STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance.

  2023cites this paper
• Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

  2023cites this paper
• Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations

  2023cites this paper
• ESCCAL-1 promotes cell-cycle progression by interacting with and stabilizing galectin-1 in esophageal squamous cell carcinoma

  2022cites this paper
• CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)

  2022cites this paper
• The Emerging Role of Extracellular Vesicles in Endocrine Resistant Breast Cancer

  2021cites this paper
• Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells

  2021cites this paper
• Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis

  2021cites this paper
• The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study.

  2021cites this paper
• Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, DpC

  2020cites this paper
• LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

  2020cites this paper
• Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer

  2019cites this paper
• Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

  2019cites this paper
• Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers.

  2018cites this paper
• Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

  2018cites this paper
• Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors

  2018cites this paper
• Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

  2018cites this paper
• Treatment for the endocrine resistant breast cancer: Current options and future perspectives.

  2017cites this paper
• Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

  2017cites this paper
• EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.

  2017cites this paper
• Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells

  2016cites this paper
• Plk 4 : prognostic markers , drivers of breast tumorigenesis and drug resistance

  2014cites this paper
• Inhibition of Chemokine (C-C Motif) Receptor 7 Sialylation Suppresses CCL19-Stimulated Proliferation, Invasion and Anti-Anoikis

  2014cites this paper
• Differential Regulation of Cyclin D1 Expression by Protein Kinase C α and ϵ Signaling in Intestinal Epithelial Cells*

  2014cites this paper
• Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies

  2014cites this paper
• Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.

  2014cites this paper
• Furanodiene enhances tamoxifen‐induced growth inhibitory activity of ERa‐positive breast cancer cells in a PPARγ independent manner

  2012cites this paper
• Cell Cycle Regulatory Proteins in Breast Cancer: Molecular Determinants of Drug Resistance and Targets for Anticancer Therapies

  2012cites this paper
• Differential Gene Expression in Tamoxifen-Resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data

  2012cites this paper
• Tamoxifen resistance in breast cancer : a proteomic approach

  2012cites this paper
• A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

  2011cites this paper
• Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

  2011cites this paper
• Commentary: Killing The Second Messenger: Targeting Loss of Cell Cycle Control in Endocrine Resistant Breast Cancer Running Title: Targeting Cell Cycle Control in Breast Cancer

  2011cites this paper
• Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers

  2010cites this paper
• DNA amplifications in breast cancer: genotypic-phenotypic correlations.

  2010cites this paper
• Cell Cycle and Anti-Estrogen Effects Synergize to Regulate Cell Proliferation and ER Target Gene Expression

  2010cites this paper
• Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

  2010cites this paper
• Ling-Zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells.

  2010cites this paper
• G1 Phase Cyclins in Cancer Development and Progression

  2010cites this paper
• A Noncompetitive Small Molecule Inhibitor of Estrogen-regulated Gene Expression and Breast Cancer Cell Growth That Enhances Proteasome-dependent Degradation of Estrogen Receptor α*

  2010cites this paper
• Detection of copy number amplification of cyclin D1 (CCND1) and cortactin (CTTN) in oral carcinoma and oral brushed samples from areca chewers.

  2009cites this paper
• Cell cycle alterations and 11q13 amplification in breast cancer -prediction of adjuvant treatment response

  2009cites this paper
• Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation

  2009cites this paper
• Iodine Alters Gene Expression in the MCF7 Breast Cancer Cell Line: Evidence for an Anti-Estrogen Effect of Iodine

  2008influential citation
• Regulation of hormonal therapy resistance by cell cycle machinery.

  2008cites this paper
• Estrogen Receptor Genomic Function Factor Receptor Signaling with Repression of Classic Tamoxifen Resistance in Breast Tumors Is Driven by Growth

  2008cites this paper
• Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

  2008cites this paper
• Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.

  2008cites this paper
• Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions

  2008cites this paper
• Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy.

  2007cites this paper
• Basic science (December 2006)

  2007cites this paper
• ERR Gamma: Does an Orphan Nuclear Receptor Link Steroid Hormone Biogenesis to Endocrine Resistance?

  2007cites this paper
• Pathways to tamoxifen resistance.

  2007cites this paper